Danaher is a diagnostic & research company located in District Of Columbia, United States, which is part of the Healthcare sector, and is traded under the ticker DHR on the NYSE exchange.
Danaher stock last closed at $163.86, up 1.2% from the previous day, and has decreased 16.57% in one year. It has underperformed other stocks in the Diagnostics & Research industry by 0.21 percentage points. Danaher stock is currently +1.82% from its 52-week low of $160.93, and -32.51% from its 52-week high of $242.80.
As of May 18, 2026, there are 707.77M shares of DHR outstanding. The market value of DHR is $115.98B. In the last 24 hours, 2.76M DHR shares were traded.
You need a brokerage account in order to access the NYSE market and buy DHR shares.
Based on our research, eToro is the best stock brokerage. Here's why:
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've selected your brokerage, it's time to fill out some personal details so you can invest in DHR today.
Now that you've opened your account on one of the best stock apps, your next step is to transfer the money for your investment:
Watch this video walkthrough for more details transferring funds into your brokerage account.
Once you have identified the best place to buy Danaher stock, it's crucial to research their stock prior to buying, so you truly comprehend the risk and upside.
WallStreetZen was built to help part-time investors perform more in-depth fundamental analysis in less time.
You can view all of the due diligence checks on DHR's stock page.
Investors use many financial metrics, analyses, models, and charts to gauge DHR's true value.
Using relative valuations metrics:
You can access more valuation analysis on DHR's stock here.
Out of 10 sell side analysts who give recommendations on DHR, the consensus analyst rating on Danaher is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
Luke Sergott, a bottom 2% analyst from Barclays maintains DHR with a strong buy rating and lowers their DHR price target from $250.00 to $230.00, on Apr 14, 2026.
Evie Koslosky, a bottom 16% analyst from Goldman Sachs maintains DHR with a strong buy rating and lowers their DHR price target from $265.00 to $230.00, on Apr 13, 2026.
Vijay Kumar, a bottom 3% analyst from Evercore ISI Group maintains DHR with a buy rating and lowers their DHR price target from $254.00 to $225.00, on Apr 6, 2026.
Tycho Peterson, a top 19% analyst from JP Morgan maintains DHR with a strong buy rating and raises their DHR price target from $270.00 to $275.00, on Jan 29, 2026.
Dan Brennan, a top 7% analyst from TD Cowen maintains DHR with a strong buy rating and raises their DHR price target from $260.00 to $270.00, on Jan 7, 2026.
TD Cowen's Dan Brennan raised their price target on Danaher (NYSE: DHR) by 3.8% from $260 to $270 on 2026/01/07. The analyst maintained their Strong Buy rating on the stock.
Danaher will report its Q4 2025 earnings on 2026/01/28.
Hiking their price target in a quarterly preview note on names in their Life Science Tools portfolio, Brennan said that although expectations for the prints are elevated after recent share price gains, many companies "already soft guided" FY 2026, setting the stage for upsides against consensus as the year unfolds.
You can dive deeper into what analysts are projecting on the Danaher stock forecast page.
Last year, DHR earnings were $3.69B. During the last 5 year, DHR's earnings have grown by -4.31% per year. This was slower than the Diagnostics & Research industry average of 1.12%.
Last year, DHR revenue was $24.78B. Over the past 5 year, DHR's revenue has increased by -0.02% per year. This was slower than the Diagnostics & Research industry average of 7.68%.
You can research DHR's earnings and revenue performance here.
In the past year, executives and large shareholders at DHR have sold more shares than they have bought.
Alan G. Spoon, Director of DHR, was the latest DHR insider to buy. They bought $237,060.24 worth of DHR shares on May 1, 2026.
Get more info about who owns DHR stock here.
Danaher pays a dividend of 0.83%, compared to the Diagnostics & Research industry's average dividend yield of 0.88%. If you owned $1,000 of DHR stock, you would have received $8.30 in the past 12 months.
Danaher dividend payments have consistently grown over the past decade but have not remained stable.
Dig into more data about Danaher dividend yield and history here.
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
You have two main options:
Press the Open Trade button and eToro will place your order.
If you require additional help with investing in stocks on eToro, watch the how to video below:
Now that you own some DHR shares, you'll want to stay up-to-date on your new shares.
Add DHR to a watchlist to see the latest developments about your DHR stock.
To summarize, here are the 6 steps you need to take to buy Danaher stock right now:
If you need a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to keep tabs on your investment in Danaher, click the button below.